Search
Pidacmeran
go.drugbank.com/drugs/DB16401InvestigationalPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
GRAd-COV2
go.drugbank.com/drugs/DB16428InvestigationalGRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423]. … This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2)[L30420, L30423].
CoVac-1
go.drugbank.com/drugs/DB16429InvestigationalSponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].
V590
go.drugbank.com/drugs/DB16437ExperimentalBy teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow protocol[L30583].
Enpatoran
go.drugbank.com/drugs/DB16501InvestigationalAdditionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis … It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327).
Upanovimab
go.drugbank.com/drugs/DB16505InvestigationalUpanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19
Collagen-polyvinylpyrrolidone
go.drugbank.com/drugs/DB16525InvestigationalCollagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation[A227733].
Orticumab
go.drugbank.com/drugs/DB16653InvestigationalOrticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).
Oxelumab
go.drugbank.com/drugs/DB16663InvestigationalOxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).